RHHBY - Roche Holding AG
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 39.90 |
| Open | 40.02 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 40.02 - 40.33 |
| 52 Week Range | 34.70 - 43.32 |
| Volume | |
| Avg. Volume | 2,294,829 |
| Market Cap | 259.508B |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 18.90 |
| EPS (TTM) | 2.13 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.28 (3.18%) |
| Ex-Dividend Date | Mar 16, 2023 |
| 1y Target Est | 46.30 |
Fair Value
Related Research
Simply Wall St.Institutions own 40% of Roche Holding AG (VTX:ROG) shares but retail investors control 45% of the company
Key Insights The considerable ownership by retail investors in Roche Holding indicates that they collectively have a...
Investor's Business DailyArcus, Iteos Soar On Roche's 'Meaningful' Results In A New Cancer Drug Class
Shares of Arcus and Iteos surged Friday after Roche provided "meaningful" evidence for a new cancer treatment class.
GlobeNewswireRoche to present new data in blood cancers and solid tumours from its broad portfolio at ASCO 2023
Basel, 26 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held 2 – 6 June. Highlights include new data spanning treatments for lymphoma and hepatocellular carcinoma (HCC): Developing new treatment options for people with blood cancers Extended follow-up data for Columvi® (glofitamab) of almost two years (20 months) from the pivot
ZacksSarepta (SRPT) Down 11% on FDA Extending DMD Gene Therapy Review
The FDA extends the review period for Sarepta's (SRPT) BLA for DMD gene therapy by almost four weeks to Jun 22. The agency may limit the use of the therapy in children aged between four and five.
Motley FoolWhy Shares of Rain Oncology Are Plummeting Today
Shares of Rain Oncology (NASDAQ: RAIN) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, to treat dedifferentiated liposarcoma, a type of cancer affecting fatty tissue, usually in the arms and legs. Rain said that milademetan, an inhibitor of the MDM2-p53 complex that reactivates p53, a known tumor inhibitor, taken orally, did not meet its primary endpoint of efficacy in a phase 3 trial to treat patients with dedifferentiated (DD) liposarcoma (LPS). Based on the disappointing results, Rain said it does not plan to pursue further development of the therapy to treat DD LPS.
ZacksRegeneron (REGN) Faces Challenges as Eylea Sales Decline
Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.
ZacksPharma Stock Roundup: FDA Nod to ABBV's Rinvoq for New Indication & Other Updates
FDA panel votes in favor of Pfizer's (PFE) experimental maternal RSV vaccine. FDA approves AbbVie's (ABBV) Rinvoq for Crohn's Disease.
BenzingaRoche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows
Roche Holdings AG's (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS) met its primary and secondary endpoints. The data showed oral fenebrutinib significantly reduced magnetic resonance imaging (MRI) markers of MS disease activity in the brain compared to placebo. Additionally, pre-clinical data have shown fenebrutinib to be potent and highly selective, and it is the only reversible inhibitor currently in Phase 3 trials for MS. Fenebrutinib s
ZacksRoche's (RHHBY) MS Drug Meets Goals in the Phase II Study
Roche's (RHHBY) investigational oral fenebrutinib meets its primary and secondary endpoints in the phase II FENopta study.
PR NewswireRoche showcases commitment to advancing innovative diagnostic solutions at WorldLab-EuroMedLab
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will be showcasing innovative laboratory solutions and digital diagnostics through - "Innovation Past, Present and Future" at this year's WorldLab-EuroMedLab 2023 in Rome, Italy, 21-25 May. Attendees will have the opportunity to experience first-hand Roche's latest technological advancements in lab automation, serum work area, molecular and point of care solutions and find out more about how the company is transforming patient care throu
Business WireGenentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People With Relapsing Forms of Multiple Sclerosis
SOUTH SAN FRANCISCO, Calif., May 17, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase II FENopta study evaluating investigational oral fenebrutinib in adults with relapsing forms of multiple sclerosis (RMS). The study met its primary and secondary endpoints, showing oral fenebrutinib significantly reduced magnetic resonance imaging (MRI) markers of MS disease activity in the brain compared to placebo. Additionally, pre-cli
- GlobeNewswire
Roche’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis
Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) trialsPhase II study met its primary and secondary endpoints by reducing the total number of new gadolinium-enhancing T1 brain lesions and significantly reducing the total number of new or enlarging T2 brain lesions compared to placeboThe safety profile of fenebrutinib was consistent with previous and ongoi
InvestorPlace3 Stocks That Are Reshaping the Future
Investors can find growth plays in many corners of the stock market, but a smart play would be looking for the stocks reshaping the future. These are companies at the forefront of a burgeoning trend that look poised to run away with a large slice of the growing market share. A good first place to look is at the population as a whole. Unfortunately, we’re getting older and more unhealthy. The WHO estimates that 1 in 6 people will be over 60 by 2030. By 2050, the proportion of the population that’
ZacksSarepta's (SRPT) DMD Gene Therapy Gets Endorsed by FDA Panel
The FDA's CTGTAC narrowly recommends granting accelerated approval to Sarepta's (SRPT) DMD gene therapy. A final decision from the agency is expected by the end of this month.
TheStreet.comThese 3 Global Drug Stocks Have a Prescription for High Yields
Let's review three pharma companies based outside the U.S. that promise reasonable valuations and solid dividend yields.
- Zacks
Pharma Stock Roundup: BAYRY Mixed Q1 Results, AZN, RHHBY Regulatory/Pipeline Updates
Bayer (BAYRY) announces mixed Q1 results. AstraZeneca's (AZN) Ultomiris gets approval for a new rare disease indication in the EU.
- Reuters
Column: Despite Trump pardon, ex-InterMune CEO owes millions in legal fees, Delaware judge finds
May 11 (Reuters) - (The opinions expressed here are those of the author, a columnist for Reuters.) Scott Harkonen, the onetime CEO of biotech company InterMune Inc, spared no expense when he was indicted in 2008 for wire fraud based on what prosecutors said was a deceptive press release in 2002 about clinical trial results for an InterMune drug. Harkonen spent millions of dollars trying to clear his name through the courts, all to no avail. In the last days of Donald Trump's presidency, Trump granted a pardon to Harkonen.
ZacksHalozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/Y
Halozyme (HALO) first-quarter earnings and revenues miss estimates. The company reiterates its guidance for 2023.
Business WireFDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
SOUTH SAN FRANCISCO, Calif., May 09, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Vabysmo® (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). The sBLA is based on results from the Phase III BALATON and COMINO studies that demonstrated treatment with Vabysmo provided early and sustai
- GlobeNewswire
FDA accepts application for Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)
Acceptance based on two phase III studies that demonstrated early and sustained vision improvement with Vabysmo, meeting primary endpoint of non-inferiority compared to afliberceptApplication was further supported by data showing Vabysmo achieved rapid and robust drying of retinal fluid If approved, RVO would be the third indication for Vabysmo in addition to neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME)Vabysmo is currently approved in 60 countries
- Simply Wall St.
Investing in Roche Holding (VTX:ROG) five years ago would have delivered you a 47% gain
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses is...
- Investing.com
Weekly biotech pulse: Big catalysts on tap for Sarepta, Roche, Eyenovia, and more
By Vlad Schepkov
FreightWavesOcean carriers: Keep rail storage fee disputes at STB
Shippers want Congress to expand FMC’s power over rail storage fees, but shipping lines say the power is already in the hands of the STB. The post Ocean carriers: Keep rail storage fee disputes at STB appeared first on FreightWaves.
- GlobeNewswire
Roche launches Institute of Human Biology to accelerate breakthroughs in R&D by unlocking the potential of human model systems
The Institute of Human Biology aims to better predict which drug candidates are safe and most effective in patients by evolving and increasing the use of human model systems. Human model systems are miniature living 'replicas' of human tissues and organs that also have the potential to reduce reliance on animal testing. The institute brings together scientists from academia and industry to lead the broad adoption of human model systems in pharmaceutical R&D as well as in clinical practice. Basel
ZacksSarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Sarepta (SRPT) delivers narrower-than-expected loss per share in first-quarter 2023. Total revenues beat estimates on the back of strong product sales growth during the quarter.